alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                           1,442
<SECURITIES>                                         0
<RECEIVABLES>                                    3,453
<ALLOWANCES>                                         0
<INVENTORY>                                      2,481
<CURRENT-ASSETS>                                13,112
<PP&E>                                             618
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  25,550
<CURRENT-LIABILITIES>                           11,179
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          2
<COMMON>                                           216
<OTHER-SE>                                       6,409
<TOTAL-LIABILITY-AND-EQUITY>                    25,550
<SALES>                                          6,595
<TOTAL-REVENUES>                                 6,595
<CGS>                                            4,846
<TOTAL-COSTS>                                   12,727
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 653
<INCOME-PRETAX>                                (6,191)
<INCOME-TAX>                                         3
<INCOME-CONTINUING>                            (6,194)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (6,194)
<EPS-BASIC>                                      (.32)
<EPS-DILUTED>                                    (.32)


</TABLE>
IN RE B.D.H.

No. COA07-161.

Court of Appeals of North Carolina.

Filed July 17, 2007.

Certification Date August 6, 2007.

Appeal from Wilkes (04J105, 04J106, 04J107).

Case reported without published opinion. Affirmed.
Exhibit No. 11. Statement re: Computation of Per Share Earnings for the six and
                three months ended June 30, 1997 and 1996 (in thousands except
                per share data).


<TABLE>
<CAPTION>
                                                        Six Months Ended                  Three Months Ended
                                                            June 30,                           June 30,
                                                 -------------------------------      --------------------------
                                                      1997            1996                1997          1996
                                                      ----            ----                ----          ----
<S> <C>  
    Net income                                       $ 846           $ 768               $ 375         $ 449
                                                     =====           =====               =====         =====


    Weighted average shares outstanding              3,021           3,138               3,023         3,119

    Common stock equivalents due to dilutive
       effect of stock options                          96              17                  99            15
                                                     -----           -----               -----         -----

    Total weighted average common shares
       and equivalents outstanding                   3,117           3,155               3,122         3,134
                                                     =====           =====               =====         =====

    Primary earnings per share                      $ 0.27          $ 0.24              $ 0.12        $ 0.14
                                                    ======          ======              ======        ======

    Total weighted average common shares
       and equivalents outstanding                   3,117           3,155               3,122         3,134

    Additional dilutive shares using the
       end of period market value versus the
       average market value when applying
       the treasury stock method(1)                    N/A             N/A                 N/A           N/A
                                                     -----           -----               -----         -----
    Total weighted average common shares             
       and equivalents outstanding for fully
       diluted computation                           3,117           3,155               3,122         3,134
                                                     =====           =====               =====         =====

    Fully diluted earnings per share                $ 0.27          $ 0.24              $ 0.12        $ 0.14
                                                    ======          ======              ======        ======
</TABLE>


----------
(1)  Fully dilutive earnings per share are not anti-dilutive or did not result
     in dilution of three percent or more; therefore they are not separately
     presented in the consolidated statements of operations.

                                       20
[Federal Register Volume 70, Number 174 (Friday, September 9, 2005)]
[Notices]
[Page 53674]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-17933]



[[Page 53674]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552(b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Initial Review 
Group, Subcommittee I--Career Development.
    Date: October 25-26, 2005.
    Time: 8 p.m. to 3 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Marriott Crystal Gateway, 1700 Jefferson Davis Highway, 
Arlington, VA 22202.
    Contact Person: Robert Bird, PhD, Scientific Review 
Administrator, Resources and Training Review Branch, National Cancer 
Institute, National Institutes of Health, 6116 Executive Blvd., Room 
8113, MSC 8328, Bethesda, MD 20892-8328. 301-496-7978. 
<a href="/cdn-cgi/l/email-protection#e6848f948294a68b878f8ac8888f8ec8818990"><span class="__cf_email__" data-cfemail="22404b504650624f434b4e0c4c4b4a0c454d54">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: September 1, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-17933 Filed 9-9-05; 8:45 am]
BILLING CODE 4140-01-M


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
<PAGE>

                                                                    EXHIBIT 31.1

                   CERTIFICATION OF CO-CHIEF EXECUTIVE OFFICER
                   -------------------------------------------

I, David I. Fann, certify that:

1. I have reviewed this quarterly report on Form 10-Q of UST Private Equity
Investors Fund, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a
material fact or omit to state a material fact necessary to make the statements
made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

     a) designed such disclosure controls and procedures, or caused such
     disclosure controls and procedures to be designed under our supervision, to
     ensure that material information relating to the registrant, including its
     consolidated subsidiaries, is made known to us by others within those
     entities, particularly during the period in which this report is being
     prepared;

     b) evaluated the effectiveness of the registrant's disclosure controls and
     procedures and presented in this report our conclusions about the
     effectiveness of the disclosure controls and procedures, as of the end of
     the period covered by this report based on such evaluation; and

     c) disclosed in this report any change in the registrant's internal control
     over financial reporting that occurred during the registrant's most recent
     fiscal quarter (the registrant's fourth fiscal quarter in the case of an
     annual report) that has materially affected, or is reasonably likely to
     materially affect, the registrant's internal control over financial
     reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on
our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of
directors (or persons performing the equivalent functions):

     a) all significant deficiencies and material weaknesses in the design or
     operation of internal control over financial reporting which are reasonably
     likely to adversely affect the registrant's ability to record, process,
     summarize and report financial information; and

     b) any fraud, whether or not material, that involves management or other
     employees who have a significant role in the registrant's internal control
     over financial reporting.

Date: March 16, 2004


/s/ David I. Fann
--------------------------------------
David I. Fann, Co-Chief Executive
Officer
EXHIBIT 11.1

<TABLE>
<CAPTION>
                           AMF BOWLING, INC.
                COMPUTATION OF EARNINGS PER COMMON SHARE
                (IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)


                                                                   PERIOD ENDED
                                                                  DECEMBER 31,       DECEMBER 31,
                                                                    1996 (a)             1997             1998
                                                                ------------------ ----------------- ----------------
<S>                                                                   <C>                 <C>              <C>

Shares
    Weighted average number of
       common shares outstanding                                           39,713            45,249           59,717
                                                                ================== ================= ================


Net loss before extraordinary items                                     $ (19,484)        $ (32,198)      $ (125,894)
                                                                ================== ================= ================
Net loss                                                                $ (19,484)        $ (55,564)      $ (125,894)
                                                                ================== ================= ================

Net loss per share, basic and diluted:
Net loss per share before extraordinary items (b)                         $ (0.49)          $ (0.71)         $ (2.11)
Per share effect of extraordinary items (b)                                     -             (0.52)               -
                                                                ------------------ ----------------- ----------------
Net loss per share (b)                                                    $ (0.49)          $ (1.23)         $ (2.11)
                                                                ================== ================= ================
</TABLE>

------------------------------------------------

(a) For the period from the inception date of January 12, 1996 which includes
    results of operations of the acquired business from May 1, 1996 through the
    period ended December 31, 1996.

(b) Outstanding stock options and warrants are not considered as their effect is
    antidilutive.
# C_2023155EN.01003001.xml

| 2.5.2023 | EN | Official Journal of the European Union | C 155/30 |
| --- | --- | --- | --- |

2.5.2023

EN

Official Journal of the European Union

C 155/30

---

Request for a preliminary ruling from the Sąd Okręgowy w Koszalinie (Poland) lodged on 24 January 2023 — RF v Getin Noble Bank S.A.

(Case C-34/23, Getin Noble Bank)

(2023/C 155/38)

Language of the case: Polish

Referring court

Sąd Okręgowy w Koszalinie

Parties to the main proceedings

Applicant: RF

Defendant: Getin Noble Bank S.A.

Question referred

Does the prohibition laid down in Article 70(1) Directive 2014/59/EU of the European Parliament and of the Council of 15 May 2014 establishing a framework for the recovery and resolution of credit institutions and investment firms and amending Council Directive 82/891/EEC, and Directives 2001/24/EC, 2002/47/EC, 2004/25/EC, 2005/56/EC, 2007/36/EC, 2011/35/EU, 2012/30/EU and 2013/36/EU, and Regulations (EU) No 1093/2010 and (EU) No 648/2012, (1) of the European Parliament and of the Council, relate only to the possibility of securing a pecuniary claim by way of enforcement or also to the institution of any proceedings to secure claims in relation to an entity under special resolution?

---

(1)  OJ 2014 L 173, p. 190.

---
**Exhibit 32.2**





**Stratus Services Group, Inc.**


Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002


(18 U.S.C. Section 1350)





In connection with the annual report of Stratus Services Group, Inc. (the Company) on Form 10-K for the fiscal year ended September 30, 2004 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Michael A. Maltzman, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:





1.
the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2.
the information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.








Dated: December 22, 2004
By:
/s/ Michael A. MaltzmanMichael A. MaltzmanChief Financial Officer(Principal Financial and Accounting Officer)
WELLS REAL ESTATE FUND IX, L.P.



EXHIBIT 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

AND PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

(18 U.S.C. 1350)

In connection with the Quarterly Report on Form 10-Q of Wells Real Estate Fund IX, L.P. for the quarterly period ended September 30, 2006, as filed with the Securities and Exchange Commission (the
Report), the undersigned, Leo F. Wells, III, Principal Executive Officer of the corporate general partner of one of the General Partners of the Registrant, and Douglas P. Williams, Principal Financial Officer of the corporate general
partner of one of the General Partners of the Registrant, hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350), that, to the best of our knowledge and belief:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
| | --- | -------------------------------------------------------------------------------------------------------------------------------------------------------



|                                                               
|---------------------------------------------------------------
|/s/    LEO F. WELLS, III                                       
|Leo F. Wells, III Principal Executive Officer November 13, 2006



|                                                                 
|-----------------------------------------------------------------
|/s/    DOUGLAS P. WILLIAMS                                       
|Douglas P. Williams Principal Financial Officer November 13, 2006
STATE v. Jimmy Lee ROSSER.

No. 315P08.

Supreme Court of North Carolina.

August 26, 2008.

Annie M. Middleton, Assistant Attorney General, Philip E. Berger, Jr., District Attorney, for State of NC.

The following order has been entered on the motion filed on the 2nd day of July 2008 by Defendant to Review Order Denying Motion for Appropriate Relief:

"Motion Dismissed as moot by order of the Court in conference this the 26th day of August 2008."
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS OF TRANSCEND THERAPEUTICS, INC. FOR THE YEAR ENDED DECEMBER
31, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                      10,988,461
<SECURITIES>                                         0
<RECEIVABLES>                                        0
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                            16,979,754
<PP&E>                                         110,608
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                              17,425,719
<CURRENT-LIABILITIES>                        1,659,989
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        57,586
<OTHER-SE>                                  15,708,144
<TOTAL-LIABILITY-AND-EQUITY>                17,425,719
<SALES>                                      5,000,000
<TOTAL-REVENUES>                             5,000,000
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                             7,848,559
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                            (2,260,679)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (2,260,679)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (2,260,679)
<EPS-PRIMARY>                                   (0.75)
<EPS-DILUTED>                                   (0.75)


</TABLE>
DISTRICT COURT OF APPEAL OF THE STATE OF FLORIDA

FOURTH DISTRICT

ADAM JEFFREY KATZ, P.A., a Florida professional association,

and ADAM J. KATZ, individually,

Appellants,

v.

ANIEL JEROME,

Appellee.

No. 4D17-2835

[June 13, 2018]

Appeal from the Circuit Court for the Fifteenth Judicial Circuit, Palm 

Beach County; Cymonie S. Rowe, Judge; L.T. Case No. 

502013CA011596XXXXMB.

Richard S. Lubliner of Lubliner Kish PLLC, West Palm Beach, for 

appellants.

No appearance for appellee.

PER CURIAM.

Affirmed. See Evans v. McDonald, 313 F. App’x. 256, 257 (11th Cir. 

2009) (noting expert testimony in legal malpractice action is not required 

where “the lawyer's lack of care and skill is so obvious that the trier of fact 

can resolve the issue as a matter of common knowledge”); Suritz v. Kelner, 

155 So. 2d 831, 834 (Fla. 3d DCA 1963) (finding expert testimony was 

unnecessary where jury could find the attorney was negligent based on 

the facts presented by the plaintiff).

WARNER, TAYLOR and LEVINE, JJ., concur.

* * *

Not final until disposition of timely filed motion for rehearing.
[Federal Register Volume 70, Number 173 (Thursday, September 8, 2005)]
[Notices]
[Pages 53395-53396]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-17948]


=======================================================================
-----------------------------------------------------------------------

NATIONAL SCIENCE FOUNDATION


Sunshine Act; Meeting

AGENCY HOLDING MEETING: National Science Board; Audit and Oversight 
Committee.

DATE AND TIME: September 14, 2005, 11 a.m.-12 noon (e.t.).

PLACE: National Science Foundation, 4201 Wilson Boulevard, Arlington, 
VA 22230, Public Meeting Room 220.

[[Page 53396]]


STATUS: This meeting will be open to the public.

MATTERS TO BE CONSIDERED: 

Wednesday, September 14, 2005, Open Session.

Open Session (11 a.m. to 12 noon)

    Discussion of Draft Report of NSB examination of the NSF Merit 
Review System.

FOR FURTHER INFORMATION CONTACT: Dr. Michael P. Crosby, Executive 
Officer and NSB Office Director, (703) 292-7000, http://www.nsf.gov/nsb.

Michael P. Crosby,
Executive Officer and NSB Office Director.
[FR Doc. 05-17948 Filed 9-6-05; 3:46 pm]
BILLING CODE 7555-01-M
EXHIBIT 32.2
                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of OraLabs Holding Corp. (the "Company") on
Form 10-KSB/A for the period ending December 31, 2003 as filed with the
Securities and Exchange Commission on the date hereof (the "Report") I, Gary H.
Schlatter, Chief Executive Officer of the Company, certify, pursuant to 18 USC
SS. 1350, as adopted pursuant to SS. 906 of the Sarbanes-Oxley Act of 2002, that
to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.





/s/ Gary H. Schlatter
------------------------------------------
Gary H. Schlatter, Chief Executive Officer



Dated: May 26, 2004